Theravance, Inc. (NASDAQ:THRX)
| CAPS Rating |
|
|---|---|
| Open | $16.61 |
| Previous Close | $17.35 |
| Daily Range | $15.69 - $16.85 |
| 52-Week Range | $12.91 - $28.95 |
| Market Cap | $1.40B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 829,311 |
| Average Daily Volume | 0 |
THRX
VS S&P 500 (SPY)
How do you think THRX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
THRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
THRX News and Commentary
- Theravance Shares Tanked: What You Need to Know – The Motley Fool
- 3 Pharmaceutical Buyout Targets to Consider in 2012 – Blogs @ The Motley Fool
- Investors: 1 Dividend to Buy, 1 Dividend to Sell – The Motley Fool
- Glaxo and Theravance Suffer Setback - Analyst Blog – NASDAQ
- Glaxo and Theravance Suffer Setback - Analyst Blog – NASDAQ
- Theravance Shares Got Crushed: What You Need to Know – The Motley Fool
- CORRECT: Glaxo Plans Filing Advair Replacement Relovair In Mid-2012 – SmartMoney
- Glaxo Plans Filing Advair Replacement Relovair In Mid-2012 – SmartMoney
- Here's What 1 of the Best Investors Is Buying – The Motley Fool
- Risk-Reward Balanced at Theravance - Analyst Blog – NASDAQ
- Smart Money Picks: Biotech Stocks With Bullish Short Trends – The Motley Fool
- Options Market Picks: 9 Highly Liquid Stocks With Bullish Options Sentiment – The Motley Fool
- GlaxoSmithKline Invests $1.3M In Theravance – SmartMoney
- Smart Money Trends: 5 Biotech Stocks Being Bought Up By Insiders and Institutions – NASDAQ
- Biotech Exit Rush: Investors Are Freaked Out by Biotech's Hurdles – NASDAQ
- Here's What Seth Klarman Is Buying – The Motley Fool
- Biotech Analysts See Buying Opportunities From Sell-Off – The Motley Fool
- Investing 101: The Top 10 Losers That Have Seen Insider Buying – The Motley Fool
- A Quick Glance at the Stocks in David Swensen's Yale Portfolio – The Motley Fool
- GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair – The Motley Fool
RSS Headlines
Fool UK
